Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.

Ensem Therapeutics has divulged compounds acting as cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer.

Merck Sharp & Dohme LLC has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.

Eikon Therapeutics Inc. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and respiratory disorders.

Shanghai Curegene Pharmaceutical Co. Ltd. has described nucleoside prodrugs reported to be useful for the treatment of viral infections.

Humanwell Healthcare (Group) Co. Ltd. has divulged Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of pain, autoimmune disease and dermatological disorders.

Zhuhai Yufan Biotechnologies Co. Ltd. has identified molecular glue degraders comprising an E3 ubiquitin protein ligase-binding agent covalently bound to a DNA-binding protein Ikaros (IKZF1)-targeting moiety acting as IKZF1 degradation inducers potentially useful for the treatment of cancer, autoimmune disease, neurodegeneration and inflammatory disorders.

Vanderbilt University has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia and sleep disorders.

Jiangsu Vcare Pharmatech Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor (ER) degradation inducers.